Oraya Therapeutics, the developer of a low energy X-ray beam that can safely deliver radiation therapy to the into the eye, is expanding its presence in Europe. The 20-minute one-time procedure is designed to reduce the need for anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration.
Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew of Phase III trials in which the drug slashed patients' bad cholesterol.
Researchers have found a way to use nanoparticles to deliver drugs that can "wake up" the immune system and fortify its natural response to harmful cancer cells in the body.
Researchers at the National University of Singapore have developed a method for delivering the polypeptide antibiotic actinomycin D with modified, self-assembled DNA nanopyramid against bacteria such as E. coli and Staphylococcus aureus, the bug causes staph infections.
With investors focused almost exclusively on earnings and R&D programs today, Merck quietly managed to slip in news of a setback in its quarterly report, noting that the FDA has rejected its marketing application for the fertility treatment corifollitropin alfa.
Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.
Google isn't just searching the Internet. The company will soon search the insides of people's bodies for new biomarkers by collecting their urine, blood, saliva and tears as part of its Baseline Study initiative.
AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.
Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its cholera vaccine candidate, PXVX0200.
I caught up with Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, last week, prior to his address at the National Press Club in downtown Washington, DC. Other media outlets joined in later. Here are some takeaways from his speech on antibiotic resistance, as well as our conversation.